This phase I/II trial is testing an immunotherapy alone and in combination with other anti-cancer treatments in patients with multiple myeloma who have got worse or not responded to earlier treatment.
This trial is treating patients with multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This trial includes a dose exploration (DE) phase, which will be used to evaluate the safety and tolerability of belantamab mafodotin when administered in combination with other anti-cancer treatments. A RP2D for each combination treatment will be identified based on the safety and preliminary efficacy in DE. This will be followed by a cohort expansion (CE) phase which will evaluate the clinical activity of the combination treatment in comparison to belantamab mafodotin monotherapy in additional participants.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More